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A novel patient cluster in antineutrophil cytoplasmic antibody (ANCA)‑associated vasculitis (AAV) 
may be identified in Japan. We performed multiple correspondence and cluster analysis regarding 
427 clinically diagnosed AAV patients excluding eosinophilic granulomatosis with polyangiitis. Model 
1 included the ANCA phenotype, items of the Birmingham Vasculitis Activity Score, and interstitial 
lung disease; model 2 included serum creatinine (s‑Cr) and C‑reactive protein (CRP) levels with model 
1 components. In seven clusters determined in model 1, the ANCA‑negative (n = 8) and proteinase 
3‑ANCA‑positive (n = 41) groups emerged as two distinct clusters. The other five myeloperoxidase‑
ANCA‑positive clusters were characterized by ear, nose, and throat (ENT) (n = 47); cutaneous (n = 36); 
renal (n = 256), non‑renal (n = 33); and both ENT and cutaneous symptoms (n = 6). Four clusters in 
model 2 were characterized by myeloperoxidase‑ANCA negativity (n = 42), without s‑Cr elevation 
(< 1.3 mg/dL) (n = 157), s‑Cr elevation (≥ 1.3 mg/dL) with high CRP (> 10 mg/dL) (n = 71), or s‑Cr 
elevation (≥ 1.3 mg/dL) without high CRP (≤ 10 mg/dL) (n = 157). Overall, renal, and relapse‑free 
survival rates were significantly different across the four clusters in model 2. ENT, cutaneous, and 
renal symptoms may be useful in characterization of Japanese AAV patients with myeloperoxidase‑
ANCA. The combination of s‑Cr and CRP levels may be predictive of prognosis.
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CRP  C-reactive protein
EGPA  Eosinophilic granulomatosis with polyangiitis
ENT  Ear, nose and throat; ILD
ESRD  End-stage renal disease
EULAR  European League against Rheumatism
EUVAS  European Vasculitis Study Group
GPA  Granulomatosis with polyangiitis
ILD  Interstitial lung disease
IQR  Interquartile
MPA  Microscopic polyangiitis
MPO  Myeloperoxidase
OMAAV  Otitis media with AAV
PCA  Principal component analysis
PR3  Proteinase-3
RemIT-JAV  Remission induction therapy in Japanese patients with AAV
RemIT-JAV-RPGN  Remission induction therapy in Japanese patients with AAV and rapidly progressive 
glomerulonephritis
s-Cr  Serum creatinine
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a multisystem autoimmune disease 
characterized by ANCA production and small- and medium-sized blood vessel  inflammation1. Eosinophilic 
granulomatosis with polyangiitis (EGPA), Granulomatosis with polyangiitis (GPA), and microscopic polyangiitis 
(MPA), are the major categories of AAV, and proteinase 3 (PR3) and myeloperoxidase (MPO) are two major 
antigens of  ANCA2. PR3-ANCA is generally regarded as a marker for granulomatosis with polyangiitis (GPA)2, 
while MPO-ANCA is for microscopic polyangiitis (MPA)/renal-limited  vasculitis3. Though various classifica-
tion and diagnostic criteria combining clinical symptoms and ANCA phenotypes have been used in the clinical 
study and practice, unclassifiable patients are still  remain3. Moreover, a recent genome-wide association study 
has revealed that the ANCA phenotype better classified patients with GPA and MPA than clinical classification, 
suggesting that better classification should be  required4.
Cluster analysis is a statistical method of exploratory data mining for grouping objects into homogenous 
groups by their similarity. A previous report using cluster analysis for AAV suggested that ANCA phenotype 
and renal involvement could better predict prognosis than clinical classification such as granulomatosis with 
polyangiitis (GPA) and  MPA5. We previously have reported predominance of MPA and MPO-ANCA positivity 
as common characteristics in Japan and other East Asian  countries6, which is in marked contrast to the results 
of studies previously reported from Western  countries7,8. Based on the above mentioned genetic study, there 
should be marked differences between the genetic backgrounds of AAV patients in Japan and Western  countries4. 
Thus, another relevant cluster may be determined in Japan where MPO-ANCA and MPA are dominant among 
AAV patients.
Though prognostic factors in AAV have not yet fully explored, the Remission Induction Therapy in Japanese 
Patients with AAV (RemIT-JAV) study revealed that the European Vasculitis Study Group (EUVAS) criteria for 
disease severity was useful for predicting the prognosis of Japanese patients with  AAV6, while the Remission 
Induction Therapy in Japanese Patients with AAV and Rapidly Progressive Glomerulonephritis (RemIT-JAV-
RPGN) study added the superior suitability of the Japanese RPGN clinical grading system compared to the 
EUVAS criteria for disease  severity8. The Japanese RPGN clinical grading system consists of four components: 
age, serum creatinine (s-Cr) levels, lung complication, and C-reactive protein (CRP) levels. CRP levels have 
been reported to be useful for predicting mortality and for distinguishing between active AAV and  remission9,10. 
However, no study has elucidated the characteristics of AAV that are represented by CRP levels.
The objectives of the present study were (1) to explore novel clinical groups of MPA, GPA, and unclassifiable 
patients using cluster analysis in terms of clinical phenotype or severity assessment; (2) to evaluate the associa-
tions between the determined clusters and clinical outcomes; and (3) to elucidate the characteristics of AAV 
associated with CRP levels.
Methods
Database. This study used data from the RemIT-JAV study and RemIT-JAV-RPGN study. Twenty-two ter-
tiary care institutions (university hospitals and referring hospitals) participated in RemIT-JAV, and 53 partici-
pated in RemIT-JAV-RPGN. The patients with newly diagnosed AAV were prospectively enrolled from April 
2009 to December 2010 into RemIT-JAV and from April 2011 to March 2014 into RemIT-JAV-RPGN. There is 
not an overlap of patients between the two studies. The criteria for enrolment in RemIT-JAV and RemIT-JAV-
RPGN were as follows: (1) clinical diagnosis of AAV by the site investigators, (2) fulfillment of the criteria for 
primary systemic vasculitis, as proposed by the European Medicines Agency (EMEA)  algorithm11, and (3) ini-
tiation of immunosuppressive treatment based on the discretion of the site investigators. The exclusion criteria 
in RemIT-JAV and RemIT-JAV-RPGN were (1) an age less than 20 years, (2) serological evidence of hepatitis B 
or C virus infection, and (3) a history of malignancy. The classification of AAV was conducted based on EMEA 
 algorithm11.
Clinical variables. Data from the two studies were merged in a single dataset. Forty-two patients with EGPA 
were excluded because EGPA phenotypes are markedly different from phenotypes presented by other types of 
AAV patients. We also excluded eight patients whose PR3-ANCA results were unavailable at diagnosis.
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In the present study, nine items of the Birmingham Vasculitis Activity Score (BVAS) 2003, ILD, s-Cr lev-
els, serum CRP levels, and the ANCA phenotype (proteinase-3 (PR3)-ANCA or MPO-ANCA) were used as 
clinical variables. Interstitial lung disease (ILD) was confirmed radiologically. The BVAS 2003 includes follow-
ing symptoms: general; cutaneous; mucous membrane/eye; ear, nose and throat (ENT); chest; cardiovascular; 
abdominal; renal; and nervous system  symptoms12. ILD was selected as a candidate clinical variable because of 
the high prevalence in our  cohorts3,8. The patients enrolled in RemIT-JAV and RemIT-JAV-RPGN were evalu-
ated at 3, 6, 12, 18, and 24 months after diagnosis and at the time of relapse. We collected the following outcome 
measures: remission rate, overall survival rate, end-stage renal disease (ESRD)-free survival rate, and relapse 
rate. Remission was defined as BVAS = 0 (new or worse) on two consecutive occasions that occurred at least one 
month  apart13. ESRD was defined as dependence on dialysis or an irreversible increase in s-Cr level of > 5.6 mg/
dL (500 μmol/L)14. Relapse was defined as the recurrence or new onset of clinical signs and symptoms attribut-
able to active  vasculitis15.
Statistical analysis. Cluster analysis was performed based on two models. Model 1 included the nine clini-
cal symptoms considered in the BVAS, PR3-ANCA and MPO-ANCA, and ILD for assessment of the clinical 
phenotype. Model 2 included laboratory data for two additional characteristics (s-Cr and CRP levels) for the 
assessment of disease  severity8–10. The s-Cr levels were categorized on the basis of the thresholds of the EUVAS 
criteria for disease severity (1.3 mg/dL (120 μmol/L) and 5.6 mg/dL (500 μmol/L))15, and the CRP levels were 
categorized on the basis of the Japanese RPGN clinical grading system (2.6 mg/dL and 10.0 mg/dL), which could 
stratify the prognosis in patients with AAV and/or  RPGN8,16. There are no missing data regarding these variables 
among enrolled patients.
At first, multiple correspondence analysis was performed to select candidate variables. Using principal com-
ponent analysis (PCA), the contribution rate of each variable was calculated according to the distance from 
principal component 1 and principal component 2. Variables that explained at least 90% of the total contribution 
rates were included for the cluster analysis. Subsequently, hierarchical clustering based on the Ward method, 
followed by consolidation (K-means algorithm), was performed using the determined variables. To decide the 
optimal number of clusters, a dendrogram was plotted in each model. We determined the clusters by the branches 
and vertical distance based on each dendrogram. A dominant clinical feature (> 75% or 0% of patients in each 
cluster) was used to name each cluster.
For evaluation of the discrimination ability of the determined characteristics in each cluster, classification 
tree analysis was conducted subsequently. The predictive accuracies of the algorithms were calculated using the 
observed numbers of individuals allocated to the predicted classes. The overall survival, ESRD-free survival, 
cumulative remission, and relapse rates were analyzed using the Kaplan–Meier method and the log-rank test 
across the determined clusters.
To explore the clinical symptoms associated with the serum CRP levels, multiple linear regression analysis 
was performed using stepwise backward selection to minimize the Bayesian information criterion. Among all 
63 items of the BVAS and ILD, the items observed in > 5% of enrolled patients were used as candidate variables. 
The prevalence of each BVAS item or ILD is shown in Supplementary Table S1.
All statistical analyses were performed by a biostatistician using the JMP version 10.0.2 statistical package 
for Windows (SAS Institute Inc., Cary, NC, USA) or R 3.2.3 (R Foundation for Statistical Computing, Vienna, 
Austria). A two-tailed P < 0.05 was considered statistically significant. When comparing seven or four clusters, 
the statistical significance was determined by P < 0.05/7 or P < 0.05/4 by the Bonferroni correction to adjust for 
multiple testing.
Ethics approval and consent to participate. This study was approved by the Ethics Committee of 
the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (authorization 
number: No. 1909-016), and conducted according to the Declaration of Helsinki and the Ethical Guidelines 
for Epidemiological Research in Japan. Written informed consent was obtained from each participant, and the 
study protocol was approved by the ethics committee of each participating hospital. The RemIT-JAV study and 
RemIT-JAV-RPGN study were registered with the University Hospital Medical Information Network Clinical 
Trials Registry (UMIN000001648 and 000005136).
Results
Patient characteristics and clinical outcomes. Of 477 patients with AAV enrolled in the two cohort 
studies, 427 patients were enrolled in the present study (142 patients from the RemIT-JAV and 285 patients from 
the RemIT-JAV-RPGN study, Supplementary Fig. S1). The enrolled patient characteristics are shown in Supple-
mentary Table S2. Among enrolled 427 patients, fifteen patients showed positive results for both types of ANCA. 
Remission was achieved in 88% (n = 376) of the enrolled patients, and relapses occurred among 15% (n = 57) of 
the remitted patients. During the median (IQR) observational periods of 730 (654–730) days, 47 deaths and 46 
ESRDs were reported.
Cluster analysis in model 1. On the basis of the contribution rates of the candidate variables in model 
1 by PCA, eight variables were selected with 91% of total contribution rates: MPO-ANCA, PR3-ANCA, ENT 
symptoms, nervous system symptoms, general symptoms, renal symptoms, cutaneous symptoms, and ILD (Sup-
plementary Table S3). By the dendrogram of model 1, seven clusters were suggested (Supplementary Fig. S2). 
Patient characteristics were compared across seven clusters, as presented in Table 1. Cluster 1 was characterized 
by PR3-ANCA positivity (34 of 41, 82.9%) and Cluster 2 by ANCA negativity (8 of 8, 100%). All patients in the 
other five clusters were MPO-ANCA-positive. Among the five clusters of MPO-ANCA-positive patients, Cluster 
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Table 1.  Comparison of patient characteristics across seven clusters based on model 1. Values expressed as the 
number of patients or median (interquartile). CRP C-reactive protein, GPA granulomatosis with polyangiitis, 
ILD interstitial lung disease, MPA microscopic polyangiitis, MPO-ANCA myeloperoxidase-antineutrophil 
cytoplasmic antibody, PR3-ANCA proteinase-3-antineutrophil cytoplasmic antibody.
Cluster 1 (n = 41)
PR3-ANCA (+)
Cluster 2 (n = 8)
ANCA (−)
Cluster 3 (n = 47) 
MPO-ANCA (+)
ENT
Cluster 4 (n = 36) 
MPO-ANCA (+)
Cutaneous
Cluster 5 (n = 256) 
MPO-ANCA (+)
Renal
Cluster 6 (n = 33) 
MPO-ANCA (+)
Non-renal
Cluster 7 (n = 6) 
MPO-ANCA (+)
ENT with cutaneous
Female/male 22/19 3/5 28/19 22/14 141/115 23/10 4/2
Age (years) 63 (58–74) 64 (60–73) 72 (62–79) 69 (59–76) 73 (65–79) 75 (68–80) 71 (62–75)
GPA (%) 34 (83) 2 (25) 34 (72) 2 (6) 11 (4) 1 (3) 2 (33)
MPA (%) 3 (7) 2 (25) 12 (26) 25 (69) 218 (85) 7 (21) 3 (50)
Unclassifiable (%) 4 (10) 4 (50) 1 (2) 9 (25) 27 (11) 25 (76) 1 (17)
MPO-ANCA (%) 2 (5) 0 47 (100) 36 (100) 256 (100) 33 (100) 6 (100)
PR3-ANCA (%) 34 (82.9) 0 4 (8.5) 1 (2.8) 7 (2.7) 0 1 (16.7)
Serum creatinine (mg/dL) 0.79 (0.6–1.2) 0.64 (0.57–0.71) 1.2 (0.83–3.5) 0.96 (0.66–19) 2.1 (0.97–4.0) 0.67 (0.57–0.82) 0.99 (0.75–1.6)
CRP (mg/dL) 3.9 (1.2–11) 4.3 (1.2–11) 11 (5.6–15) 7.4 (2.6–12) 6.5 (1.4–12) 8.1 (4.6–12) 9.3 (0.44–16.3)
ILD (%) 3 (7) 3 (38) 12 (26) 8 (22) 126 (49) 28 (85) 5 (83)
General (%) 26 (63) 8 (100) 37 (79) 29 (81) 155 (61) 25 (76) 4 (67)
Cutaneous (%) 4 (10) 4 (50) 0 36 (100) 8 (3) 1 (3) 6 (100)
Mucous membranes/
eyes (%) 15 (37) 1 (13) 14 (30) 2 (6) 16 (6) 2 (6) 0
Ear nose and throat (%) 33 (80) 2 (25) 47 (100) 1 (3) 0 0 6 (100)
Chest (%) 18 (44) 2 (25) 29 (62) 13 (36) 98 (38) 9 (27) 3 (50)
Cardiovascular (%) 3 (7) 0 3 (6) 3 (8) 25 (10) 0 0
Abdominal (%) 1 (2) 0 0 0 3 (1) 0 0
Renal (%) 22 (54) 1 (13) 37 (79) 28 (78) 256 (100) 0 4 (67)
Nervous system (%) 12 (29) 7 (88) 21 (45) 21 (58) 62 (24) 9 (27) 4 (67)
Figure 1.  Classification tree analysis of 427 patients with antineutrophil cytoplasmic antibody-associated 
vasculitis in model 1. The dominant clinical feature (over 80%) is used to name each class. The observed 
number of individuals allocated to each class is shown in each column. The algorithm was initiated on the 
basis of ANCA positivity and was subsequently allocated according to organ involvement. Among 47 patients 
with PR3-ANCA, 34 were assigned to Cluster 1. Among 15 patients with ANCA negativity, 8 were assigned 
to Cluster 2. Among 49 patients with MPO-ANCA and ENT symptoms, 48 were assigned to Cluster 3 or 7. 
Among 43 patients with MPO-ANCA and skin symptoms, 34 were assigned to Cluster 4. The rest were assigned 
to predicted clusters by cluster analysis. The overall concordance rate was 93%. ENT ear, nose and throat, 
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3 was characterized by ENT symptoms (47 of 47, 100%), Cluster 4 by cutaneous symptoms (36 of 36, 100%), 
and Cluster 5 by renal symptoms (256 of 256, 100%). No patient in Cluster 6 had renal symptoms. All patients 
in Cluster 7 had both ENT and cutaneous symptoms. Classification tree analysis based on specified character-
istic in each cluster is presented in Fig. 1. First, 47 patients were classified into the PR3-ANCA-positive group. 
Then, 15 patients were classified into the ANCA-negative group. Among the MPO-ANCA-positive patients, 49 
patients were classified as having ENT symptoms, 43 patients were classified as the cutaneous group, 241 patients 
as the renal group (all patients were in Cluster 5), and the remaining patients exhibited no renal symptoms (i.e., 
non-renal group). In 397 (93%) patients, the classification tree analysis showed consistent results with cluster 
analysis when Cluster 7 (ENT with cutaneous symptoms) was combined with Cluster 3 (ENT symptoms).
The overall survival rate was not significantly different across the clusters in model 1 (P = 0.325, Supplemen-
tary Fig. S3A). Cluster 4 (MPO-ANCA-positive patients with cutaneous disease) tended to show worse survival, 
but not significantly worse survival (P = 0.026), compared to Cluster 1 (PR3-ANCA-positive patients, Supple-
mentary Fig. S3A). The ESRD-free survival rate differed significantly across the seven clusters (P = 0.039), but 
no significant differences were found between any two clusters (Supplementary Fig. 3B). Cumulative remission 
(Supplementary Fig. S4A) and relapse-free survival (Supplementary Fig. 4B) rates were not significantly different 
across the clusters in model 1 (P = 0.239 and 0.250, respectively).
Cluster analysis in model 2. Next, PCA of model 2 (including the CRP and s-Cr levels) was performed, 
and nine variables were selected with a total of 93% contribution rates: MPO-ANCA, PR3-ANCA, general 
symptoms, ENT symptoms, CRP, nervous system symptoms, creatinine, mucous membrane/eye symptoms; and 
renal symptoms (Supplementary Table S4). By the dendrogram of model 2, four clusters were suggested (Fig. 2). 
Patient characteristics were compared across four clusters, as presented in Table 2. Cluster 1 was characterized 
by MPO-ANCA negativity (39 of 42, 93%), Cluster 2 by s-Cr elevation (≥ 1.3 mg/dL (115 μmol/L)) with high 
CRP (> 10 mg/dL) (54 of 71, 76%; renal with high CRP), Cluster 3 by without s-Cr elevation (< 1.3 mg/dL) (10 of 
157, 89%; non-renal), and Cluster 4 by s-Cr elevation (≥ 1.3 mg/dL) without high CRP (≤ 10 mg/dL) (117 of 157, 
75%; renal without high CRP). Classification tree analysis based on specified characteristics in each cluster is 
presented in Fig. 3. First, 47 patients were classified as MPO-ANCA-negative. Among the MPO-ANCA-positive 
patients, 178 patients were classified as a non-renal group, 65 patients as a renal group with high CRP level, and 
137 patients as a renal group without high CRP level. Classification tree analysis was consistent with cluster 
analysis in model 2; 343 (80%) patients were classified in the same cluster.
The overall survival rates differed significantly across the four clusters (P < 0.001, Fig. 4A). Cluster 2 
(MPO-ANCA-positive renal patients with high CRP) showed a worse survival rate compared to Cluster 1 
(MPO-ANCA-negative, P = 0.002) and Cluster 3 (MPO-ANCA-positive non-renal patients, P < 0.001, Fig. 4A). 
The ESRD-free survival rate also differed significantly among the 4 clusters (P < 0.001, Fig. 4B), and Cluster 
2 exhibited a worse ESRD-free survival rate compared to Cluster 1 (P < 0.001) and Cluster 3 (P < 0.001). The 
cumulative remission rates did not differ (P = 0.173, Supplementary Fig. S5A), but relapse-free survival was 
significantly different across the four clusters of model 2 (P = 0.023, Supplementary Fig. S5B). Cluster 2 and Clus-
ter 3 exhibited worse relapse-free survival rates compared with Cluster 1 (P = 0.006 and P = 0.009, respectively, 
Supplementary Fig. S5B). When comparing MPO-ANCA negative patients (Cluster 1) with other MPO-ANCA 
positive clusters, the remission and overall survival rates showed no statistical difference (P = 0.585 and P = 0.065) 
while ESRD-free survival and relapse-free survival rates were better in MPO-ANCA negative cluster compared 
to other MPO-ANCA positive clusters (P = 0.020 and P = 0.014).
Figure 2.  Dendrograms for cluster model 2 for antineutrophil cytoplasmic antibody-associated vasculitis. The 
dendrogram shows the clustering process of model 2 resulting in four clusters. Cluster 1 was characterized by 
MPO-ANCA negativity, Cluster 2 by s-Cr elevation with high CRP (CRP > 10 mg/dL and creatinine ≥ 1.3 mg/
dL), Cluster 3 by without s-Cr elevation (s-Cr < 1.3 mg/dL), and Cluster 4 by s-Cr elevation (s-Cr ≥ 1.3 mg/
dL) without high CRP (≤ 10 mg/dL). MPO-ANCA myeloperoxidase-antineutrophil cytoplasmic antibody, CRP 
C-reactive protein, s-Cr serum creatinine.
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Table 2.  Comparison of patient characteristics across four clusters based on model 2. Values expressed as the 
number of patients or median (interquartile). CRP C-reactive protein, GPA granulomatosis with polyangiitis, 
ILD interstitial lung disease, MPA microscopic polyangiitis, MPO-ANCA myeloperoxidase-antineutrophil 
cytoplasmic antibody, PR3-ANCA proteinase-3-antineutrophil cytoplasmic antibody.
Cluster 1
MPO-ANCA (−) (n = 42)
Cluster 2
Renal with high CRP 
(n = 71)
Cluster 3
Non-renal (n = 157)
Cluster 4
Renal without high CRP 
(n = 157)
Female/male 22/20 32/39 96/61 93/64
Ages (years) 63 (59–73) 73 (65–79) 73 (64–78) 73 (64–78)
GPA (%) 34 (81) 19 (27) 23 (15) 10 (6)
MPA (%) 5 (12) 49 (69) 84 (53) 132 (84)
Unclassifiable (%) 3 (7) 3 (4) 50 (32) 15 (10)
MPO + ANCA (%) 3 (7) 71 (100) 150 (96) 156 (99)
PR3-ANCA (%) 33 (79) 6 (9) 5 (3) 3 (2)
Serum creatinine (mg/dL) 0.8 (0.6–1.4) 2.9 (1.6–4.6) 0.76 (0.62–1.0) 2.4 (1.3–4.5)
 < 1.3 (%) 30 (71) 8 (11) 140 (89) 38 (24)
 ≥ 1.3, < 5.5 (%) 11 (26) 47 (66) 17 (11) 92 (59)
 ≥ 5.5 (%) 1 (2) 16 (23) 0 27 (17)
CRP (mg/dL) 3.9 (1–11) 13 (11–17) 9.6 (6.1–13) 1.6 (0.2–5.1)
 < 2.6 (%) 14 (33) 0 7 (4) 99 (63)
 ≥ 2.6, ≤ 10 (%) 15 (36) 10 (14) 74 (47) 56 (36)
 > 10 (%) 13 (31) 61 (86) 76 (48) 2 (1)
ILD (%) 6 (14) 31 (44) 86 (55) 62 (39)
General (%) 26 (62) 60 (85) 140 (89) 58 (37)
Cutaneous (%) 5 (12) 12 (17) 32 (20) 10 (6)
Mucous membranes/eyes 
(%) 18 (43) 8 (11) 19 (12) 5 (3)
Ear nose and throat (%) 34 (81) 23 (32) 19 (12) 13 (8)
Chest (%) 18 (43) 49 (69) 56 (36) 49 (31)
Cardiovascular (%) 3 (7) 14 (20) 3 (2) 14 (9)
Abdominal (%) 1 (2) 2 (3) 1 (1) 0
Renal (%) 24 (57) 71 (100) 105 (67) 148 (94)
Nervous system (%) 13 (31) 27 (38) 85 (54) 11 (7)
Figure 3.  Classification tree analysis of 427 patients with antineutrophil cytoplasmic antibody-associated 
vasculitis in model 2. The dominant clinical feature (over 75%) is used to name each class. The observed number 
of individuals allocated to each class is shown in each column. The algorithm was initiated on the basis of MPO-
ANCA positivity and was subsequently allocated by s-Cr and CRP levels. Among 47 patients with MPO-ANCA 
negativity, 39 were assigned to Cluster 1. Among 178 MPO-ANCA-positive patients without s-Cr elevation, 
133 were assigned to Cluster 3. Among 65 MPO-ANCA-positive patients with s-Cr elevation and high CRP, 
54 were assigned to Cluster 3. Among the remining 137 patients with s-Cr elevation and without high CRP, 
117 were assigned to Cluster 4. The overall concordance rate was 80%. CRP C-reactive protein, MPO-ANCA 
myeloperoxidase-antineutrophil cytoplasmic antibody, s-Cr serum creatinine.
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Association between CRP and clinical symptoms. We explored the clinical symptoms associated with 
the CRP level using BVAS items and ILD. Univariate regression analysis revealed that ‘fever’, ‘weight loss’, ‘myal-
gia’, ‘arthralgia/arthritis’, ‘conductive hearing loss’, ‘pleural effusion/pleurisy’, ‘infiltrate’, ‘massive hemoptysis/
alveolar hemorrhage’, ‘sensory peripheral neuropathy’, and ‘mononeuritis multiplex’ associated with CRP levels. 
A multiple linear regression analysis exhibited that fever (β coefficient (95% confidence interval) 2.1 (1.5–2.6)), 
myalgia (2.5 (2.0–3.1)), massive hemoptysis/alveolar hemorrhage (1.3 (0.4–2.2)), and mononeuritis multiplex 
(1.2 (0.5–2.0)) independently associated with CRP levels (Supplementary Table S5). Renal symptoms showed no 
association with CRP levels.
Discussion
This is the first study that classified Japanese AAV patients by cluster analysis and evaluated the prognosis 
among the determined clusters. In the first model, seven distinct clinical clusters were identified: ENT, cutane-
ous, non-renal, and renal in MPO-ANCA-positive patients; PR3-ANCA-positive patients; and ANCA-negative 
patients. Moreover, clusters separated on the basis of CRP and s-Cr levels predicted prognosis with respect to 
overall, ESRD-free, and relapse-free survival rates. Further, this is the first study to evaluate the symptoms which 
contribute to the CRP level, and the analysis suggested that the CRP level represented general, pulmonary, and 
neural symptoms but not renal symptoms.
Although the ANCA phenotype and the ENT, cutaneous, and renal symptoms are universal and specific 
features of AAV, it is possible that the priority for each feature in the classification of AAV is different among 
different ethnicities or regions. In this study, PR3-ANCA-positive and ANCA-negative patients were first sepa-
rated. A previous report from a Western country demonstrated that PR3-ANCA positivity was used to classify 
patients with GPA and MPA into two clusters in the final branch of  classification5. In that study, 56% of patients 
was PR3-ANCA-positive and 32% was MPO-ANCA-positive, while, in our study, 89% was MPO-ANCA-positive 
but only 11% was PR3-ANCA-positive. Although the importance of the ANCA phenotype in our study was 
consistent with that in the previous study, this apparent difference in ANCA positivity might determine the 
distinction between two clusters according to the ANCA phenotype ahead of clinical  symptoms5. Subsequently, 
patients with ENT symptoms were classified among MPO-ANCA-positive patients. Although ENT symptoms 
are generally regarded as surrogate markers for  GPA11, which is characterized by PR3-ANCA, there are several 
reports regarding MPO-ANCA-positive GPA, in which the majority of patients show ENT symptoms, consist-
ent with our  results17,18. Recently, the notion of otitis media with AAV (OMAAV) irrespective of the ANCA 
phenotype has  emerged19, which frequently accompanies facial palsy and hypertrophic pachymeningitis. Thus, 
ENT symptoms may be a surrogate clinical marker for AAV even in MPO-ANCA-positive AAV. After clas-
sification based on ENT symptoms, patients with cutaneous symptoms were identified. This cluster exhibited 
various organ involvements except for ENT symptoms (Table 1). According to the previous  report20, cutaneous 
vasculitis rarely preceded the renal and pulmonary symptoms in patients with MPA. Cutaneous vasculitis was 
also reported to be associated with general, renal, pulmonary, and nervous system  symptoms20,21. Indeed, the 
cutaneous cluster showed a tendency toward worse overall survival in our study. Therefore, patients with cutane-
ous symptoms should be carefully evaluated for systemic organ involvements. Finally, clusters with and without 
Figure 4.  Overall survival and ESRD-free survival rates according to clusters of model 2. (A) Overall survival 
rates and (B) ESRD-free survival rates. Analysis was performed using a log-rank test. Cluster 2 showed a worse 
survival rate compared to Cluster 1 (P = 0.0024) and Cluster 3 (P = 0.0003). Cluster 2 exhibited worse ESRD-free 
survival rate compared to Cluster 1 (P < 0.0001) and Cluster 3 (P < 0.0001). One patient in Cluster 3 and one 
patient in Cluster 4 were excluded from these analyses because of the missing follow-up data. ESRD end-stage 
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renal symptoms were separated. In our previous report, using a different cohort, renal vasculitis was observed 
in 75% of MPO-ANCA-positive  AAV22. In the present study, we have been able to confirm that renal symptoms 
are specific for MPO-ANCA-positive MPA and GPA.
s-Cr and CRP levels could be good biomarkers for the prediction of prognosis. In the present study, 
patients with ≥ 1.3 mg/dL (120 μmol/L) of s-Cr levels showed poor overall and ESRD-free survival. Patients 
with < 1.3 mg/dL of s-Cr levels were categorized as having the localized type or early systemic type of  AAV15. 
The BVAS has categorized s-Cr levels into 3 groups: 1.4 mg/dL (125 μmol/L)–2.8 mg/dL (249 μmol/L), 2.8 mg/
dL (250 μmol/L)–5.6 mg/dL (499 μmol/L), and ≥ 5.6 mg/dL (500 μmol/L)12. The 1996 Five-Factor Score also 
included s-Cr levels of > 1.6 mg/dL as the indicator for renal  insufficiency23. Although previous reports have 
shown that better renal function at diagnosis is associated with improved survival and renal  outcome24–26, the 
presence of renal insufficiency might be more important than the severity of renal insufficiency for the prediction 
of prognosis in patients with AAV. In addition to the s-Cr levels, the CRP levels could differentiate the prognosis 
of AAV. Previous reports have showed that an increase in CRP levels before treatment of AAV was associated with 
relapse and  mortality9,10. Though the appropriate cut-off of CRP for the prediction of AAV outcomes had not been 
determined, we have reported the utility of the Japanese RPGN clinical grading system for predicting prognosis, 
which consists of age, s-Cr levels, lung complication, and CRP levels where the CRP levels were separated by 
2.6 mg/dL and 10.0 mg/dL8. In the present study, we were able to validate these cut-offs of CRP levels. Further 
studies are needed to confirm the roles of s-Cr and CRP levels as biomarkers for prognosis in patients with AAV.
CRP is a surrogate marker for important organ involvements, except for renal symptoms. The CRP levels 
have not been observed to increase in patients with glomerulonephritis including IgA nephropathy, membra-
nous nephropathy, and minimal change disease compared to that in  controls27. Consistent with these previous 
observations, the CRP levels associated with fever, myalgia, and pulmonary and neurological vasculitis but not 
with renal symptoms in the present study. Although several previous reports have described that CRP could be 
a biomarker in the patients with systemic lupus erythematosus or AAV with renal  involvements28,29, CRP levels 
may be related to organ involvements other than the kidney in the patients with AAV. Therefore, it could be 
rational and relevant to perform a combined evaluation of s-Cr and CRP as indicators of the severity of renal and 
non-renal symptoms, respectively, for predicting prognosis in patients with AAV. Importantly, these biomarkers 
are modifiable by treatment. Hence, future research should elucidate whether improvements in CRP and/or s-Cr 
levels by treatments can predict prognosis.
Several limitations of this study should be acknowledged. First, we could not validate our classification mod-
els. Different populations are required for the validation of our results, which will be conducted in the near future. 
Second, MPO-ANCA-positive MPA is dominant in the population of Japan in contrast to the dominance of 
PR3-ANCA in the Western population. However, this point might be strength of our study because new insights 
for clinical characteristics were provided by different cluster analyses in Western populations. Third, AAV was 
diagnosed clinically by the site investigators, though all patients were fulfilled the criteria for primary systemic 
vasculitis and classified by the EMEA algorithm. Forth, the treatment strategy was decided at the discretion of 
each attending physician; therefore, it is possible that patients with higher s-Cr levels were treated intensively, 
leading to underestimation of outcomes. Nevertheless, patients with higher s-Cr levels showed worse overall and 
renal survival, supporting the relevance of renal vasculitis in AAV. Fifth, BVAS items with low prevalence were 
excluded from the analysis of the association with CRP levels. Among the excluded items, congestive cardiac 
failure, peritonitis, bloody diarrhea, and ischemic abdominal pain have been reportedly related to survival in 
patients with  AAV30. Therefore, careful workup for these cardiovascular and abdominal involvements may be 
necessary, regardless of CRP levels.
Conclusions
In summary, we have identified novel clusters of AAV among Japanese patients. We have also identified s-Cr 
level, CRP level, and MPO-ANCA negativity as prognostic biomarkers for overall, ESRD-free, and relapse-free 
survival. Further, we found that CRP was associated with non-renal symptoms such as general, pulmonary and 
nervous system symptoms but not with renal symptoms.
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